Gilead Sciences, Inc. vs Microchip Technology Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B), while Microchip Technology Inc. trades at $82.15 (market cap $43.99B). The key difference: Gilead Sciences, Inc. is far larger — about 3.8× Microchip Technology Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | MCHP | |
|---|---|---|
Market Cap | $168.35B | $43.99B |
Sector | Health | Technology |
52-Week High | $155.80 | $102.97 |
52-Week Low | $110.56 | $49.02 |
Enterprise Value | $191.42B | $49.12B |
Dividend Yield | 2.42% | 2.25% |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →